Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1;117(3):491-494.
doi: 10.14309/ajg.0000000000001608.

An Electronic Decision Support Intervention Reduces Readmissions for Patients With Cirrhosis

Jeremy Louissaint  1 , Katie Grzyb  2 , Linda Bashaw  2 , Rima A Mohammad  3 , Neehar D Parikh  1 , Elliot B Tapper  1
Affiliations

An Electronic Decision Support Intervention Reduces Readmissions for Patients With Cirrhosis

Jeremy Louissaint et al. Am J Gastroenterol. .

Abstract

Introduction: Rifaximin use in combination with lactulose is associated with a decreased risk of overt hepatic encephalopathy (HE).

Methods: We prospectively evaluated the impact of an interruptive electronic medical record alert to indicate rifaximin for patients with cirrhosis and HE on lactulose.

Results: The intervention was associated increased rifaximin utilization, particularly for nongastroenterology and hospitalist services odds ratio 1.20 95% confidence interval (1.09-1.31). For patients with HE, the intervention was associated with a lower readmission risk-adjusted subdistribution hazard ratio 0.63 95% confidence interval (0.48-0.82).

Discussion: An interruptive alert in the electronic ordering system was associated with a lower risk of readmissions.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

Potential competing interests: E.B.T. has served on advisory boards for Mallinckrodt, Kaleido, Rebiotix, Novo Nordisk, and Bausch Health; consulted for Ambys, Axcella, Allergan, and Novartis; and has received unrestricted research grants from Valeant/Bausch and Gilead. Bausch played no role in the funding, concept, design, analysis, or writing of this study. No other author has pertinent conflicts of interest.

References

    1. Tapper EB. Building effective quality improvement programs for liver disease: A systematic review of quality improvement initiatives. Clin Gastroenterol Hepatol 2016;14(9):1256–65. e1253. - PubMed
    1. Rosenblatt R, Cohen-Mekelburg S, Shen N, et al. Cirrhosis as a comorbidity in conditions subject to the hospital readmissions reduction program. Am J Gastroenterol 2019;114(9):1488–95. - PubMed
    1. Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: A multistate population-based cohort study. Clin Gastroenterol Hepatol 2016;14(8):1181–8.e2. - PubMed
    1. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362(12):1071–81. - PubMed
    1. Tapper EB, Aberasturi D, Zhao Z, et al. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther 2020;51(12):1397–405. - PMC - PubMed

Publication types

MeSH terms